Quest Diagnostics Q3 Revenue Jumps 13.2%, Net Income Up 8.4%

Ticker: DGX · Form: 10-Q · Filed: 2025-10-21T00:00:00.000Z

Sentiment: bullish

Topics: Healthcare Diagnostics, Earnings Growth, Cost Savings, AI Integration, Debt Reduction, Shareholder Value, Operational Efficiency

Related Tickers: DGX, LH

TL;DR

**DGX is executing on efficiency and growth, making it a solid buy as it leverages AI to boost margins and reduce debt.**

AI Summary

Quest Diagnostics Inc. (DGX) reported robust financial performance for the three and nine months ended September 30, 2025. Net revenues for the three months increased by 13.2% to $2,816 million from $2,488 million in the prior year, and for the nine months, they rose by 13.5% to $8,229 million from $7,251 million. Net income attributable to Quest Diagnostics shareholders grew by 8.4% to $245 million for the three-month period, up from $226 million, and by 15.1% to $747 million for the nine-month period, compared to $649 million in 2024. Diluted earnings per share increased to $2.16 from $1.99 for the quarter and to $6.57 from $5.74 for the nine months. The company's 'Invigorate' program, a multi-year initiative, aims to achieve 3% annual cost savings and productivity improvements through automation and AI, offsetting inflationary pressures. Business acquisitions, net of cash acquired, significantly decreased to $51 million for the nine months ended September 30, 2025, from $1,781 million in the same period of 2024, indicating a shift in capital allocation. Long-term debt decreased to $5,171 million from $5,615 million at December 31, 2024, reflecting substantial debt repayments of $1,011 million during the nine-month period.

Why It Matters

Quest Diagnostics' strong revenue and net income growth, coupled with its 'Invigorate' program, signals a healthy operational trajectory that could attract investors seeking stable healthcare sector plays. The strategic shift away from large acquisitions, evidenced by the significant drop in acquisition spending from $1,781 million to $51 million, suggests a focus on organic growth and efficiency, which could improve long-term profitability and shareholder returns. For employees, the Invigorate program's emphasis on automation and AI could lead to job role changes, while customers may benefit from enhanced digital experiences and improved service quality. In a competitive diagnostic services market, DGX's ability to drive cost savings and productivity through technology could strengthen its market position against rivals like LabCorp.

Risk Assessment

Risk Level: medium — While Quest Diagnostics shows strong financial performance, the company faces ongoing reimbursement pressures and labor cost increases, which the Invigorate program aims to offset with 3% annual cost savings. Additionally, the increase in deferred income tax liabilities to $378 million from $278 million due to the One Big Beautiful Bill Act (OBBBA) could impact future cash tax payments, despite the company's belief that the OBBBA will not materially impact its statement of operations.

Analyst Insight

Investors should consider holding or initiating a position in DGX, given its consistent revenue and net income growth, coupled with a clear strategy to enhance productivity through the Invigorate program. Monitor the effectiveness of the Invigorate program's 3% annual cost savings in mitigating inflationary pressures and reimbursement challenges. The reduction in long-term debt and share repurchases also indicate sound capital management.

Financial Highlights

revenue
$8,229M
total Debt
$5,171M
net Income
$747M
eps
$6.57
revenue Growth
+13.5%

Revenue Breakdown

SegmentRevenueGrowth
Diagnostic Information Services (DIS)$2,816M+13.2%
Diagnostic Information Services (DIS)$8,229M+13.5%

Key Numbers

Key Players & Entities

FAQ

What were Quest Diagnostics' key financial results for the third quarter of 2025?

For the three months ended September 30, 2025, Quest Diagnostics reported net revenues of $2,816 million, a 13.2% increase from $2,488 million in the prior year. Net income attributable to Quest Diagnostics grew by 8.4% to $245 million, up from $226 million in Q3 2024.

How did Quest Diagnostics' earnings per share change in the first nine months of 2025?

Quest Diagnostics' diluted earnings per share for the nine months ended September 30, 2025, increased to $6.57, up from $5.74 in the same period of 2024. Basic EPS also rose to $6.66 from $5.80.

What is the 'Invigorate' program at Quest Diagnostics and what are its goals?

The 'Invigorate' program is a multi-year initiative by Quest Diagnostics designed to drive 3% annual cost savings and productivity improvements across its value chain. It leverages automation and artificial intelligence to enhance patient services, logistics, laboratory operations, and revenue services, aiming to offset inflationary pressures and improve quality.

How has Quest Diagnostics' acquisition strategy changed in 2025?

Quest Diagnostics significantly reduced its business acquisition spending, net of cash acquired, to $51 million for the nine months ended September 30, 2025. This is a substantial decrease from $1,781 million in the same period of 2024, indicating a shift towards internal growth and efficiency rather than large-scale external expansion.

What impact did the One Big Beautiful Bill Act (OBBBA) have on Quest Diagnostics' financial statements?

The OBBBA, enacted in July 2025, made permanent key tax provisions like 100% bonus depreciation and domestic research cost expensing. This led to an increase in Quest Diagnostics' consolidated deferred income tax liabilities to $378 million as of September 30, 2025, from $278 million at December 31, 2024, primarily due to these elements.

What is Quest Diagnostics doing to manage its debt?

Quest Diagnostics actively managed its debt, making repayments of $1,011 million during the nine months ended September 30, 2025. This resulted in a reduction of long-term debt to $5,171 million as of September 30, 2025, from $5,615 million at December 31, 2024.

How does Quest Diagnostics use technology to improve its operations?

Quest Diagnostics is leveraging automation and artificial intelligence through its 'Invigorate' program to improve productivity and quality across its entire value chain. This includes enhancing patient services, logistics, laboratory operations, and the digital experience for customers.

What are the primary customer channels for Quest Diagnostics' diagnostic information services?

Quest Diagnostics provides diagnostic information services to a broad range of customers within its primary channels: physicians (including those associated with ACOs and FQHCs), hospitals, and patients and consumers. Other customers include health plans, employers, and government agencies.

What is the risk level associated with investing in Quest Diagnostics based on this filing?

The risk level is medium. While Quest Diagnostics demonstrates strong financial growth and a clear strategy for efficiency, it faces ongoing industry challenges such as reimbursement pressures and rising labor costs. The impact of new accounting standards and tax legislation, like the OBBBA, also introduces some uncertainty, though the company expects no material impact on its statement of operations.

What was the net cash provided by operating activities for Quest Diagnostics in the first nine months of 2025?

For the nine months ended September 30, 2025, Quest Diagnostics generated $1,421 million in net cash provided by operating activities. This represents a significant increase from $870 million in the same period of 2024, reflecting improved operational cash generation.

Risk Factors

Industry Context

The diagnostic information services industry is characterized by its critical role in healthcare, providing essential insights for diagnosis and treatment. Key trends include increasing demand for specialized testing, the integration of digital health solutions, and a focus on cost containment by payers and providers. Companies like Quest Diagnostics leverage extensive laboratory networks and data analytics to drive efficiency and improve patient outcomes.

Regulatory Implications

The healthcare industry is subject to extensive regulation, including compliance with HIPAA, CLIA, and evolving reimbursement policies. Changes in tax legislation, such as the OBBBA, also present regulatory considerations. Quest Diagnostics must navigate these complex regulatory landscapes to ensure continued operations and compliance.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]

Key Dates

Glossary

Diagnostic Information Services (DIS)
Quest Diagnostics' primary business segment providing diagnostic insights from laboratory testing. (This is the core revenue-generating segment for the company.)
Invigorate Program
A multi-year initiative by Quest Diagnostics focused on achieving 3% annual cost savings and productivity improvements through automation and AI. (Key strategy to combat inflation and improve operational efficiency.)
Participating Securities
Securities that share in the earnings of the company, often including preferred stock or certain employee awards, which affect the calculation of EPS. (A small deduction from net income is made for these securities before calculating EPS available to common stockholders.)
One Big Beautiful Bill Act (OBBBA)
Recent legislation enacted in July 2025 that makes permanent key tax provisions from the Tax Cuts and Jobs Act of 2017. (Impacts the company's tax strategy and potential cash tax payments.)
Business Acquisitions, net of cash acquired
The cost of acquired businesses minus any cash or cash equivalents obtained in the transaction. (Indicates a significant shift in capital allocation strategy, with a sharp decrease in M&A spending compared to the prior year.)

Year-Over-Year Comparison

Quest Diagnostics reported a strong year-over-year performance, with net revenues increasing by 13.2% for the quarter and 13.5% for the nine months ended September 30, 2025. Net income also saw substantial growth of 8.4% and 15.1% respectively, leading to higher diluted EPS. The company has significantly reduced its long-term debt by $1,011 million, indicating a proactive approach to financial management. A notable change is the dramatic decrease in business acquisition spending, down from $1,781 million to $51 million year-over-year, signaling a shift in strategic investment priorities.

Filing Stats: 4,654 words · 19 min read · ~16 pages · Grade level 20 · Accepted 2025-10-21 06:31:10

Key Financial Figures

Filing Documents

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Page

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) Index to unaudited consolidated financial statements filed as part of this report: Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2025 and 2024 2 Consolidated Statements of Comprehensive Income for the Three and Nine Months Ended September 30, 2025 and 2024 3 Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024 4 Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2025 and 2024 5 Consolidated Statements of Stockholders' Equity for the Three and Nine Months Ended September 30, 2025 and 2024 6

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 28

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk See Item 2. "Management's Discussion and Analysis of Financial Condition and Results of Operations" 40

Controls and Procedures

Item 4. Controls and Procedures

Controls and Procedures

Controls and Procedures 40 1 Table of Contents QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (unaudited) (in millions, except per share data) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net revenues $ 2,816 $ 2,488 $ 8,229 $ 7,251 Operating costs and expenses and other operating income: Cost of services 1,867 1,677 5,474 4,865 Selling, general and administrative 501 448 1,463 1,304 Amortization of intangible assets 39 32 117 90 Other operating expense, net 23 1 5 7 Total operating costs and expenses, net 2,430 2,158 7,059 6,266 Operating income 386 330 1,170 985 Other income (expense): Interest expense, net ( 66 ) ( 49 ) ( 200 ) ( 136 ) Other income, net 8 15 18 27 Total non-operating expense, net ( 58 ) ( 34 ) ( 182 ) ( 109 ) Income before income taxes and equity in earnings of equity method investees 328 296 988 876 Income tax expense ( 77 ) ( 65 ) ( 233 ) ( 205 ) Equity in earnings of equity method investees, net of taxes 8 6 35 14 Net income 259 237 790 685 Less: Net income attributable to noncontrolling interests 14 11 43 36 Net income attributable to Quest Diagnostics $ 245 $ 226 $ 747 $ 649 Earnings per share attributable to Quest Diagnostics' common stockholders: Basic $ 2.18 $ 2.01 $ 6.66 $ 5.80 Diluted $ 2.16 $ 1.99 $ 6.57 $ 5.74 Weighted average common shares outstanding: Basic 112 112 112 111 Diluted 113 113 113 112 The accompanying notes are an integral part of these statements. 2 Table of Contents QUEST DIAGNOSTICS INCORPORATED AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024 (unaudited) (in millions) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Net income $ 259 $ 237 $ 790 $ 685 Other comprehensive income (loss): Foreign cur

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) (in millions, unless otherwise indicated) 1. DESCRIPTION OF BUSINESS Background Quest Diagnostics Incorporated and its subsidiaries ("Quest Diagnostics" or the "Company") work across the healthcare ecosystem to create a healthier world, one life at a time. The Company's diagnostic information services ("DIS") business provides diagnostic insights from the results of its laboratory testing to empower people, physicians, and organizations to take action to improve health outcomes. Derived from one of the world's largest databases of de-identifiable clinical lab results, the Company's diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve healthcare management. In the right hands and with the right context, the Company's diagnostic insights can inspire actions that transform lives and create a healthier world. The Company provides services to a broad range of customers within its primary customer channels - physicians (including those associated with accountable care organizations ("ACOs") and Federally Qualified Health Centers ("FQHCs")), hospitals, and patients and consumers. Other customers include health plans, employers, emerging retail healthcare providers, government agencies, pharmaceutical companies and other commercial clinical laboratories. The Company offers broad access to clinical testing through a network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. The Company's large in-house staff of medical and scientific experts, including medical directors, scientific directors, genetic counselors and board-certified geneticists, provide medical and scientific consultation to healthcare providers and patients regarding the Company's tests and test results, and help them best utilize Quest Dia

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED (unaudited) (in millions, unless otherwise indicated) participating securities, by the weighted average number of common shares outstanding after giving effect to all potentially dilutive common shares outstanding during the period. Potentially dilutive common shares include the dilutive effect of outstanding stock options and performance share units granted under the Company's Amended and Restated Employee Long-Term Incentive Plan ("ELTIP") and its Amended and Restated Non-Employee Director Long-Term Incentive Plan ("DLTIP"), as well as the dilutive effect of accelerated share repurchase agreements, if applicable. Earnings allocable to participating securities include the portion of dividends declared as well as the portion of undistributed earnings during the period allocable to participating securities. New Accounting Standards to be Adopted In December 2023, the Financial Accounting Standards Board ("FASB") issued a new accounting standard which will require companies to make additional income tax disclosures. The pronouncement is effective for annual filings for the year ended December 31, 2025. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows. In November 2024, the FASB issued a new accounting standard which will require companies to disaggregate certain income statement expenses. The pronouncement is effective for annual filings for the year ended December 31, 2027 and for interim periods within the year ended December 31, 2028. The Company does not expect the adoption of this standard to have a material impact on its results of operations, financial position or cash flows. In September 2025, the FASB issued a new accounting standard which impacts internal-use software accounting by removing all references to software development project stages such that the guidance is neutral to different softwa

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED (unaudited) (in millions, unless otherwise indicated) 3. EARNINGS PER SHARE The computation of basic and diluted earnings per common share was as follows (in millions, except per share data): Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Amounts attributable to Quest Diagnostics' common stockholders: Net income attributable to Quest Diagnostics $ 245 $ 226 $ 747 $ 649 Less: Earnings allocated to participating securities 2 1 4 3 Earnings available to Quest Diagnostics' common stockholders – basic and diluted $ 243 $ 225 $ 743 $ 646 Weighted average common shares outstanding – basic 112 112 112 111 Effect of dilutive securities: Stock options and performance share units 1 1 1 1 Weighted average common shares outstanding – diluted 113 113 113 112 Earnings per share attributable to Quest Diagnostics' common stockholders: Basic $ 2.18 $ 2.01 $ 6.66 $ 5.80 Diluted $ 2.16 $ 1.99 $ 6.57 $ 5.74 The following securities were not included in the calculation of diluted earnings per share due to their antidilutive effect: Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Stock options and performance share units — — — 1 4. RESTRUCTURING ACTIVITIES AND IMPAIRMENT CHARGES Invigorate Program The Company is engaged in a multi-year program called Invigorate, which includes structured plans to drive savings and improve productivity across the value chain, including in such areas as patient services, logistics and laboratory operations, revenue services, information technology and procurement. The Invigorate program aims to deliver 3 % annual cost savings and productivity improvements to partially offset pressures from the current inflationary environment, including labor and benefit cost increases and reimbursement pressures. The Company is leveraging automation and artificial intelligence to improve productivity and also

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED (unaudited) (in millions, unless otherwise indicated) Three Months Ended September 30, Nine Months Ended September 30, 2025 2024 2025 2024 Employee separation costs $ 6 $ 7 $ 18 $ 21 Asset impairment charges 5 — 29 — Total restructuring and impairment charges $ 11 $ 7 $ 47 $ 21 The Company's pre-tax restructuring charges for the three and nine months ended September 30, 2025 included $ 6 million and $ 18 million, respectively, of employee separation costs associated with various workforce reduction initiatives as the Company continued to restructure its organization. Additionally, during the three and nine months ended September 30, 2025, the Company recorded impairment charges of $ 5 million and $ 29 million, respectively, on certain long-lived assets related to the exit of a business. Of the total restructuring and impairment charges incurred during the three months ended September 30, 2025, $ 2 million, $ 4 million and $ 5 million were recorded in cost of services, selling, general and administrative expenses and other operating expense, net, respectively. Of the total restructuring and impairment charges incurred during the nine months ended September 30, 2025, $ 8 million, $ 10 million and $ 29 million were recorded in cost of services, selling, general and administrative expenses, and other operating expense, net, respectively. The Company's pre-tax restructuring charges for the three and nine months ended September 30, 2024 were $ 7 million and $ 21 million, respectively, entirely related to employee separation costs associated with various workforce reduction initiatives as the Company continued to restructure its organization. Of the total restructuring charges incurred during the three months ended September 30, 2024, $ 4 million and $ 3 million were recorded in cost of services and selling, general and administrative expenses, respectively. Of the total restructuring charges incurred duri

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS – CONTINUED (unaudited) (in millions, unless otherwise indicated) Three Months Ended September 30, 2024 Nine Months Ended September 30, 2024 Pro forma net revenues $ 2,588 $ 7,700 Pro forma net income attributable to Quest Diagnostics $ 222 $ 647 Pro forma earnings per share attributable to Quest Diagnostics' common stockholders: Basic $ 1.97 $ 5.78 Diluted $ 1.95 $ 5.72 Acquisition of select assets of Spectra Laboratories During February 2025, the Company entered into a definitive agreement to acquire select clinical testing assets and select dialysis-related water testing assets of Fresenius Medical Care's wholly-owne

View on Read The Filing